Please provide your email address to receive an email when new articles are posted on . The EULAR/American College of Rheumatology 2019 classification criteria for systemic lupus erythematosus did not ...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...
Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...
All patients with lupus should receive hydroxychloroquine and, during chronic maintenance treatment, glucocorticoids should be minimized and withdrawn when possible, according to a 2019 update to the ...
The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. For the 2023 ...
SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only ...
SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, ...
SAN DIEGO - The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) will present the draft of new classification criteria for systemic lupus erythematosus (SLE) ...
June 19, 2009 (Copenhagen, Denmark) — New recommendations for the diagnosis and management of systemic lupus erythematosus (SLE) with neuropsychiatric manifestations were presented here at EULAR 2009: ...
TORONTO, June 10, 2020 (GLOBE NEWSWIRE) -- Eli Lilly and Company presented new data for OLUMIANT® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020). Highlights from OLUMIANT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback